Expedit ed Review of Human Subject Research Policy

Scope
Applies to the Institutional Review Board (IRB) staff when processing new applications, modifications, and continuing review reports and research for which Mayo Clinic is the Reviewing IRB.

Table of Contents
Eligibility for Expedited Review
Expedited Review
IRB Oversight of Expedited Review
Research Categories Eligible for Expedited Review
Review of Protected Populations (Subpart B, C or D)
Modifications to Research Initially Approved by a Convened IRB
Modifications to Research Initially Approved by Expedited Review
Continuing Review

Purpose
To set forth the parameters for when the IRB may review new applications, modifications, and continuing review reports by an expedited procedure as well as requirements for the expedited review process.

Policy
The IRB permits the use of expedited review procedures for eligible human subject research activities, as defined by federal regulations.

Eligibility for Expedited Review
1. The IRB may use an expedited review procedure to review any of the following:
   a. Research that involves no more than minimal risk and which appears on the following list of expedited review categories authorized by 45 CFR 46.110 and 21 CFR 56.110.
   b. Minor changes in previously approved research during the period for which approval is authorized.
   c. Research for which limited IRB review is a condition of exemption under 45 CFR 46.104(d)(2)(iii), or (d)(3)(i)(C).

Expedited Review
1. An expedited review must be performed by the IRB Chair or by an experienced IRB member designated by the IRB Chair, i.e. a member with demonstrated knowledge and application of research ethics in human subject protections of at least one year.
2. Reviewers have access to and review the same materials that are available for convened IRB review.
3. The criteria for approval using the expedited procedure are the same as those for review by a convened IRB.
4. The reviewers may exercise all of the authorities of the IRB except that the reviewers may not disapprove the research.

5. A research activity may be disapproved only after review in accordance with convened IRB procedures.

6. The reviewer will make one of the following determinations regarding the application:
   a. Approved as minimal risk research
   b. The research is exempt from the requirements outlined in 45CFR46.
   c. The proposed activity is not research or not human subjects research and does not require IRB review (Examples: case study, quality improvement/quality assurance).
   d. Revisions and/or additional information required.
   e. Forward to convened IRB.

7. Documentation of the review, action taken by the reviewer, and any specific findings required by federal regulations must be documented in the reviewer notes in electronic IRB (IRBe).

8. In all cases, the expedited reviewer reserves the authority to refer any item to a medical reviewer and/or to the Convened IRB for review. The expedited reviewer provides specific rationale for the referral, including, but not limited to items appearing on the expedited review list that the reviewer has assessed as potentially more than minimal risk.

**IRB Oversight of Expedited Review**

IRB members are advised of research proposals which have been reviewed by the expedited procedure with a listing provided with each convened meeting agenda. This information is also included in the meeting minute history. Any member can request to review the entire IRB record associated with items reviewed by the expedited review procedure.

**Categories of Research That may be Reviewed by the IRB Using an Expedited Review Procedure**

9. Applicability:
   a. The activities listed should not be deemed to be of minimal risk simply because they are included on this list. Inclusion on this list merely means that the activity is eligible for review through the expedited review procedure when the specific circumstances of the proposed research involve no more than minimal risk to human subjects.
   b. The categories in this list apply regardless of the age of subjects, except as noted.
   c. The expedited review procedure may not be used where identification of the subjects and/or their responses would reasonably place them at risk of criminal or civil liability or be damaging to the subjects' financial standing, employability, insurability, reputation, or be stigmatizing, unless reasonable and appropriate protections will be implemented so that risks related to invasion of privacy and breach of confidentiality are no greater than minimal.
d. The expedited review procedure must not be used for classified research involving human subjects.

e. The standard requirements for informed consent (or its waiver, alteration, or exception) apply regardless of the type of IRB review (expedited or convened).

f. Categories 1 through 7 pertain to initial, modifications and continuing review.

g. Categories 8 and 9 pertain to continuing review.

**Research Categories Eligible for Expedited Review**

1. Clinical studies of drugs and medical devices only when condition (a) or (b) is met.
   a. Research on drugs for which an Investigational New Drug (IND) application (IND) is not required. (Note: Research on marketed drugs that significantly increases the risks or decreases the acceptability of the risks associated with the use of the product is not eligible for expedited review.)
   b. Research on medical devices for which an Investigational Device Exemption (IDE) application is not required or the medical device is approved (cleared) for marketing and the medical device is being used in accordance with its approved (cleared) labeling.

2. Collection of blood samples by finger stick, heel stick, ear stick, or venipuncture as follows:
   a. Collected from healthy, non-pregnant adults who weigh at least 110 pounds. For these subjects, the amounts drawn may not exceed 550 ml in an 8-week period and collection may not occur more frequently than 2 times per week; or
   b. Collected from other adults and children, considering the age, weight, and health of the subjects, the collection procedure, the amount of blood to be collected, and the frequency with which it will be collected. For these subjects, the amount drawn may not exceed the lesser of 50 ml or 3 ml per kg in an 8-week period and collection may not occur more frequently than 2 times per week.

3. Prospective collection of biological specimens for research purposes by noninvasive means. Examples:
   a. Hair and nail clippings in a non-disfiguring manner;
   b. Deciduous teeth at time of exfoliation or if routine patient care indicates a need for extraction;
   c. Permanent teeth if routine patient care indicates a need for extraction;
   d. Excreta and external secretions (including sweat);
   e. Uncannulated saliva collected either in an unstimulated fashion or stimulated by chewing gum base or wax or by applying a dilute citric solution to the tongue;
   f. Placenta removed at delivery;
   g. Amniotic fluid obtained at the time of rupture of the membrane prior to or during labor;
h. Supra- and sub gingival dental plaque and calculus, provided the collection procedure is not more invasive than routine prophylactic scaling of the teeth and the process is accomplished in accordance with accepted prophylactic techniques;

i. Mucosal and skin cells collected by buccal scraping or swab, skin swab, or mouth washings;

j. Sputum collected after saline mist nebulization.

For additional examples, refer to footnote*.

4. Collection of data through noninvasive procedures (not involving general anesthesia or sedation) routinely employed in clinical practice, excluding procedures involving x-rays or microwaves. Where medical devices are employed, they must be cleared/approved for marketing. (Studies intended to evaluate the safety and effectiveness of the medical device are not generally eligible for expedited review, including studies of cleared medical devices for new indications.)

Examples:

a. Physical sensors that are applied either to the surface of the body or at a distance and do not involve input of significant amounts of energy into the subject or an invasion of the subject's privacy;

b. Weighing or testing sensory acuity;

c. Magnetic resonance imaging;

d. Electrocardiography, electroencephalography, thermography, detection of naturally occurring radioactivity, electroretinography, ultrasound, diagnostic infrared imaging, doppler blood flow, and echocardiography;

e. Moderate exercise, muscular strength testing, body composition assessment, and flexibility testing where appropriate given the age, weight, and health of the individual.

5. Research involving materials (data, documents, records, or specimens) that have been collected, or will be collected solely for nonresearch purposes (such as medical treatment or diagnosis). **Note:** Some research in this category may be exempt from the HHS regulations for the protection of human subjects. 45 CFR 46.101(b) (4). This listing in this document refers only to research that is not exempt.

6. Collection of data from voice, video, digital, or image recordings made for research purposes.

7. Research on individual or group characteristics or behavior (including, but not limited to, research on perception, cognition, motivation, identity, language, communication, cultural beliefs or practices, and social behavior) or research employing survey, interview, oral history, focus group, program evaluation, human factors evaluation, or quality assurance methodologies. **Note:** Some research in this category may be exempt from the HHS regulations for the protection of human subjects. 45 CFR 46.101(b) (2) and (b) (3). This listing in this document refers only to research that is not exempt.

8. Continuing review of research previously approved by the convened IRB as follows:

a. Where the research is permanently closed to the enrollment of new subjects; all subjects have completed all research-related interventions; and the research remains active only for long-term follow-up of subjects;
OR

b. Where no subjects have been enrolled and no additional risks have been identified;

OR

c. Where the remaining research activities are limited to data analysis.

9. Continuing review of research, not conducted under an IND application or IDE where categories two (2) through eight (8) above do not apply but the IRB has determined and documented at a convened meeting that the research involves no greater than minimal risk and no additional risks have been identified.

*Footnote: OHRP agrees with the Food and Drug Administration’s position that for purposes of expedited review Category 3, the following procedures are considered non-invasive (9/22/11 OHRP correspondence):

a. Vaginal swabs that do not go beyond the cervical os;

b. Rectal swabs that do not go beyond the rectum; and

c. Nasal swabs that do not go beyond the nares.

Review of Protected Populations (45 CFR 46, Subparts B, C, and D)

Subpart B: Additional Protections for Pregnant Women, Human Fetuses and Neonates Involved in Research

1. Clinical studies of drugs or devices (Expedited Category 1) that involve participant contact with pregnant women, human fetuses or neonates will be forwarded to the Convened IRB for review and determination.

2. The Convened IRB will determine whether Expedited procedures may be used for continuing review of these studies in accordance with 45 CFR 46.110.

3. Proposed research projects involving the collection of data through noninvasive procedures (Expedited Category 4), may be reviewed by an IRB medical reviewer for assessment of the level of risk.

4. In all cases the Expedited Reviewer reserves the authority to refer any study involving Subpart B to a medical reviewer and/or the convened IRB for review.

Subpart C: Additional Protections Pertaining to Biomedical and Behavioral Research Involving Prisoners as Subjects

Research involving prisoners as subjects requires review by a prisoner representative of the IRB and must be forwarded to a convened IRB for review and determination.

Exception: Research aimed at involving a broader subject population that only incidentally includes prisoners may be reviewed by the expedited procedure for purposes of determining exemption from 45 CFR 46.

Subpart D: Additional Protections for Children Involved as Subjects in Research

1. Research involving children as subjects will be reviewed using Expedited procedures providing the research is no greater than minimal risk in accordance with 45 CFR 46.404.

2. In all cases, the Expedited Reviewer reserves the authority to refer any study involving Subpart D to a medical reviewer and/or the convened IRB for review.

Modifications to Research Initially Approved by a Convened IRB
1. Modifications to applications previously approved by a convened IRB may be reviewed by the expedited review process if they meet the following criteria:
   a. Modifications do not pose an increased risk to subjects;
      AND
   b. Any additional procedures fall within categories 1-7 of research that may be reviewed using the expedited procedure.
   c. Modifications constitute a minor change to previously approved research.
   d. Minor Modifications: Any modification that does not materially affect the assessment of risks and benefits.

**Modifications to Research Initially Approved by Expedited Review**

Modifications to applications previously approved by Expedited review process may be reviewed using Expedited review if they meet the following criteria:

1. With the modification implemented, the research would continue to pose no more than minimal risk to subjects,
   AND

2. The modifications do not involve any procedures that do not meet Expedited categories 1 through 7, or procedures that do not meet exemption categories 1 through 6.

**Continuing Review**

1. The "Continuing Review of Research Projects" policy outlines the criteria for research that requires, or does not require, continuing review and, when applicable, the frequency for continuing review.

2. For research requiring continuing review, the continuing review may be conducted by the Expedited review process if it meets one of the following criteria:
   a. Continuing research activities pose no more than minimal risk to subjects, as assessed by the reviewer; AND the research met the criteria for initial expedited review and continues to meet those criteria, AND all procedures continue to meet one or more of the expedited review categories [1-7] as identified at initial/previous review.
   b. Research which was previously reviewed by the convened IRB, but meets the criteria for expedited review and meets category 8(a), 8(b), or 8(c) for expedited review as defined by the Office for Human Research Protections (OHRP) and the Food and Drug Administration (FDA).
   c. Research which was previously reviewed by the convened IRB and the convened IRB determined the study meets category 9 for expedited review as defined by OHRP and the FDA.

**Policy Notes**

N/A

**Related Procedures**

N/A
Definitions

**Children**: Persons who have not attained the legal age for consent to treatments or procedures involved in the research, under the applicable law of the jurisdiction in which the research will be conducted. 45 CFR 46.402(a).

**Expedited review**: A review of research involving human subjects by the IRB chairperson or by one or more experienced reviewers designated by the chairperson from among members of the IRB in accordance with the requirements set forth in 45 CFR 46.110.

**Minimal risk**: The probability and magnitude of harm or discomfort anticipated in the research are not greater in and of themselves than those ordinarily encountered in daily life or during the performance of routine physical or psychological examinations or tests.

References

**Code of Federal Regulations**

- 45 CFR 46 Protection of Human Subjects

Owner

Michelle K. Daiss on behalf of Office for Human Research Protection

Contact

Heidi M. Hanf

Revision History

<table>
<thead>
<tr>
<th>Date</th>
<th>Synopsis of Change</th>
</tr>
</thead>
<tbody>
<tr>
<td>06/14/2022</td>
<td>Scheduled review. Transferred to standardized template. Contact and Owner updated</td>
</tr>
<tr>
<td>01/21/2019</td>
<td>Updates to reflect the 2018 Revised Common Rule. Updated the document owner.</td>
</tr>
<tr>
<td>02/06/2018</td>
<td>Scheduled review. Updated to new policy template. Added purpose statement. No other changes at this time due to AAHRPP Accreditation cycle.</td>
</tr>
<tr>
<td>08/04/2017</td>
<td>Minor revision. Updated the following definitions per Glossary review: Children, Expedited Review, and Minimal Risk.</td>
</tr>
<tr>
<td>02/24/2016</td>
<td>Scheduled review – no changes</td>
</tr>
<tr>
<td>04/28/2010</td>
<td>Approval to establish document: IRB</td>
</tr>
</tbody>
</table>